SEC Form 4 · accession 0001871615-26-000016
Guardant Health, Inc. · GH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Chris Freeman
Officer — Chief Commercial Officer
Period of report
Aug 10, 2026
Accepted (ET)
Aug 11, 2026 · 6:22 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001576280
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 10, 2026 | M | 35,412 | $110.49 | A | 100,786 | D | |
| Common Stock | Aug 10, 2026 | M | 28,193 | $28.37 | A | 128,979 | D | |
| Common StockF1 | Aug 10, 2026 | S | 3,463 | $167.3805 | D | 125,516 | D | |
| Common StockF2 | Aug 10, 2026 | S | 7,365 | $168.7909 | D | 118,151 | D | |
| Common StockF3 | Aug 10, 2026 | S | 35,364 | $169.6337 | D | 82,787 | D | |
| Common StockF4 | Aug 10, 2026 | S | 17,413 | $170.2407 | D | 65,374 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F5 | $110.49 | Aug 10, 2026 | M | 35,412 | D | — | Aug 2, 2031 | Common Stock | 35,412 | 3,620 | D |
| Stock Option (Right to Buy)F6 | $28.37 | Aug 10, 2026 | M | 28,193 | D | — | Dec 13, 2033 | Common Stock | 28,193 | 1,668 | D |
Explanation of responses
- F1Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.12 to $167.8325. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- F2Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.185 to $169.175. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.195 to $170.19. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $170.20 to $170.67. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5This represents a stock option award granted on August 3, 2021 that vested over a four-year period and is now 100% vested.
- F6This represents a stock option award granted on December 13, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2024 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.